Spark Therapeutics CEO Jeffrey Marrazzo's 2018 pay falls 27% to $3.6M

Spark Therapeutics reports 2018 executive compensation

By ExecPay News

Published: July 22, 2019

Spark Therapeutics reported fiscal year 2018 executive compensation information on July 22, 2019.
In 2018, five executives at Spark Therapeutics received on average a compensation package of $2.7M, a 11% increase compared to previous year.
Average pay of disclosed executives at Spark Therapeutics
Jeffrey D. Marrazzo, Chief Executive Officer, received $3.6M in total, which decreased by 27% compared to 2017. 50% of Marrazzo's compensation, or $1.8M, was in option awards. Marrazzo also received $394K in non-equity incentive plan, $596K in salary, $758K in stock awards, as well as $39K in other compensation.
For fiscal year 2018, the median employee pay was $182,200 at Spark Therapeutics. Therefore, the ratio of Jeffrey D. Marrazzo's pay to the median employee pay was 20 to one.
John Furey, Chief Operating Officer, received a compensation package of $2.8M, which increased by 279% compared to previous year. 43% of the compensation package, or $1.2M, was in option awards.
Daniel R. Faga, Chief Business Officer, earned $2.5M in 2018, a 15% increase compared to previous year.
Katherine A. High, President and Head of Research and Development, received $2.3M in 2018, which decreases by 8% compared to 2017.
Stephen W. Webster, Chief Financial Officer, earned $2.1M in 2018, a 1% increase compared to previous year.

Related executives

Jeffrey Marrazzo

Spark Therapeutics

Chief Executive Officer

Katherine High

Spark Therapeutics

President and Head of Research and Development

Stephen Webster

Spark Therapeutics

Chief Financial Officer

Daniel Faga

Spark Therapeutics

Chief Business Officer

John Furey

Spark Therapeutics

Chief Operating Officer

You may also like

Source: SEC filing on July 22, 2019.